TORONTO--(BUSINESS WIRE)--Paradox Immunotherapeutics (“Paradox”), a pharmaceutical company focused on the development of innovative antibody therapies that treat protein misfolding diseases, today ...
Paradox Interactive announced its intention to acquire all shares in Haemimont Games, which will bring the Bulgarian studio under the Swedish company's umbrella as a subsidiary. Paradox called the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback